Response to Comments: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer

This document is a response to public comments on the MolDX LCD for molecular biomarkers to risk-stratify patients at increased risk for prostate cancer and provides administrative details (comment period, notice and effective dates) and a title revision. It does not contain clinical coverage criteria, indications, limitations, or claim documentation requirements; refer to the referenced LCDs (DL38997 / L38985) for full coverage policy details.

"No claim-level documentation requirements or clinical documentation criteria are specified in this response; the document reports the comment period (2021-06-24 to 2021-08-07), notice period start ..."

Sign up to see full coverage criteria, indications, and limitations.